NXGN fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Nextgen Biomed Ltd. operates as a research and development company. Its primary product is Eyepen, a smart and modular device consisting of pens for injecting insulin, and helps users self-manage the treatment of diabetes by documenting the times and doses of taking insulin by injection. The company was founded on December 26, 1990 and is headquartered in Raanana, Israel.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
NXGN has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company